

Hereditary diffuse gastric cancer: association with lobular breast cancer

Kasmintan A. Schrader · Serena Masciari · Niki Boyd · Sara Wiyrick ·
Pardeep Kaurah · Janine Senz · Wylie Burke · Henry T. Lynch ·
Judy E. Garber · David G. Huntsman

Published online: 29 November 2007
© The Author(s) 2007

Abstract Hereditary diffuse gastric cancer (HDGC) has been shown to be caused by germline mutations in the gene *CDH1* located at 16q22.1, which encodes the cell–cell adhesion molecule, E-cadherin. Not only does loss of expression of E-cadherin account for the morphologic differences between intestinal and diffuse gastric cancer (DGC) variants, but it also appears to lead to distinct cellular features which appear to be common amongst related cancers that have been seen in the syndrome. As in most hereditary cancer syndromes, multiple organ sites may be commonly affected by cancer, in HDGC, lobular carcinoma of the breast (LBC) and possibly other organ sites

have been shown to be associated with the familial cancer syndrome. Given the complexity of HDGC, not only with regard to the management of the DGC risk, but also with regard to the risk for other related cancers, such as LBC, a multi-disciplinary approach is needed for the management of individuals with known *CDH1* mutations.

Keywords Hereditary diffuse gastric cancer (HDGC) · Diffuse gastric cancer · E-cadherin mutation · *CDH1* mutation · Lobular breast cancer · Screening · Prophylactic total gastrectomy

Abbreviations

DGC	diffuse gastric cancer
GC	gastric cancer
HDGC	hereditary diffuse gastric cancer
LBC	lobular breast cancer

Introduction

Despite an overall decrease in the global incidence of gastric cancer (GC) [1], the incidence of the subtype, diffuse gastric cancer (DGC) has remained stable and may even be increasing [2]. Within the past ten years, germline mutations in *CDH1*, which encodes E-cadherin, have been found [3] in over 50% of hereditary diffuse gastric cancer (HDGC) families with at least two cases of GC, with one diagnosed as DGC before the age of 50 years [4]. Within these HDGC families, we and others have noted an over-representation of lobular breast cancer (LBC) [4–8]. This observation has led to efforts to determine whether or not *CDH1* is a breast cancer susceptibility gene, distinct from

K. A. Schrader · J. Senz · D. G. Huntsman (✉)
Department of Pathology and Laboratory Medicine, University
of British Columbia, British Columbia Cancer Agency,
600 W 10th Avenue, Vancouver, BC, Canada V5Z 1L3
e-mail: dhuntsma@bccancer.bc.ca

K. A. Schrader · N. Boyd · P. Kaurah · D. G. Huntsman
Hereditary Cancer Program, British Columbia Cancer Agency,
Vancouver, BC, Canada

S. Masciari · J. E. Garber
Department of Medical Oncology, Dana-Farber Cancer Institute,
Boston, MA, USA

S. Wiyrick
Departments of Neurology and Medicine, University
of Washington, Seattle, WA, USA

W. Burke
Department of Medical History and Ethics, University
of Washington, Seattle, WA, USA

H. T. Lynch
Department of Preventive Medicine and Public Health,
Creighton University School of Medicine, Omaha, NE, USA

its gastric cancer risk. Recently our group has reported a novel germline *CDH1* truncating mutation (517insA) in an LBC family with no known history of GC [9]. Within this review we report a germline *CDH1* mutation in a second family in which breast cancer is the predominant cancer diagnosis. The management of HDGC in all patients with a particular focus on the management of the breast cancer risk associated with germline *CDH1* mutations will be discussed.

Methods

The described family was referred to the ongoing HDGC study at the British Columbia Cancer Agency from a cancer genetics clinic in Seattle, WA, USA. Informed consent was obtained from the proband by the referring genetic counselor following ascertainment of a detailed cancer family history and appropriate genetic counseling prior to germline mutation testing. Our laboratory carried out the molecular genetic testing for the *CDH1* mutation on a research basis. Approval for the HDGC study is by the clinical research ethics board of the University of British Columbia.

The proband (IV-4) was diagnosed with widely metastatic lobular breast cancer at age 53 years (Fig. 1a). Her family, of


European ancestry, had a history of breast cancer diagnoses occurring in an autosomal dominant fashion on the maternal side of the family where her mother, aunt, and first cousin developed breast cancer in their 50's. Due to her high-risk pedigree *BRCA1*, *BRCA2*, and *PTEN* genetic testing was undertaken and all were negative. *CDH1* testing was also pursued.

Results

All 16 exons were amplified for DHPLC analysis [6]. For exon 10 of *CDH1*, the initial amplicon failed and was therefore analyzed by direct sequencing and thus revealed a donor splice site mutation, 1565 + 1G > A (Fig. 1b). Due to its position at a donor splice site, this mutation is regarded as pathogenic [10].

The proband's sisters (IV-2 and IV-6) participated in all aspects of the proband's genetic consultation. They were appropriately concerned about their risk of breast cancer, but had not thought much about the possibility of getting gastric cancer until the *CDH1* mutation was found. IV-2 and IV-6 had predictive genetic testing for the *CDH1* mutation testing and both were found to be negative. Other family members are being informed about the availability of predictive genetic testing.

Fig. 1 (a) Pedigree of family reported showing a predominance of breast cancer. (b) Sequence from family carrying 1565 + 1G→A mutation



Discussion

E-cadherin

CDH1 (OMIM *192090), located on chromosome 16q22.1 encodes, E-cadherin, an epithelial transmembrane cell–cell adhesion molecule and member of the cadherin superfamily of glycoproteins. In a zipper-like fashion, its extracellular domain forms calcium-dependent homodimers between the E-cadherin molecules of adjacent epithelial cells, to act as the primary mediator of epithelial cell adhesion at the adherens junction complex [11]. Through interactions of its cytoplasmic tail with multiple signalling and structural molecules, such as the catenins, E-cadherin, maintains cellular adhesion and epithelial architecture with this link to the cytoskeleton. The cytoplasmic tail of E-cadherin directly associates with β -catenin and γ -catenin which in turn binds to the f-actin microfilaments of the cytoskeleton, directly or through α -catenin [12]. p120-catenin also associates with E-cadherin's cytoplasmic tail at a different site, the juxta-membrane domain, and acts to both strengthen the adhesion between cells and regulate cadherin membrane trafficking and degradation [13, 14]. E-cadherin is considered to have an invasion suppressor role, where decreased expression permits cells to dissociate from each other in order to migrate and invade [15]. In cancers, this manifests as increased infiltrative and metastatic potential [16]. E-cadherin is also thought to act as a tumour suppressor, potentially through its interaction with the multipurpose β -catenin molecule which is an effector of the WNT signalling pathway [17]. Loss of E-cadherin can result in β -catenin release from the membrane and translocation to the nucleus where it complexes

with Tcf/Lef-1 transcription factors to initiate transcription of WNT responsive genes [18]. Activation of these genes have been implicated in tumourigenesis through the WNT signalling pathway as seen in adenomatous polyposis coli (APC) [19]. In support of the role of E-cadherin as a tumour suppressor is the observation of abnormal or absent E-cadherin expression in precursor lesions of DGC and LBC, where the phenomenon is seen in in situ signet ring cell carcinomas found in prophylactic gastrectomy specimens from germline *CDH1* mutation carriers [20] and the lobular carcinoma in situ lesions seen adjacent to invasive lobular breast cancers [21]. These examples suggest that loss of E-cadherin is an early or even tumour-initiating event, however the actual molecular basis of such a potential role of E-cadherin in such cases is unknown.

Inactivating *CDH1* mutations are found in 50% of sporadic DGCs [22, 23] and cluster between exons seven and nine [11], in contrast with the low percentage of mutations seen in sporadic intestinal type GCs [23]. Decreased expression of E-cadherin in DGCs may account for morphologic differences between intestinal and DGC variants [24]. Unlike somatic *CDH1* mutations, germline mutations associated with DGC are distributed throughout the gene [7] (Fig. 2). In the cancers from individuals with *CDH1* mutations, *CDH1* acts as a classic tumour suppressor gene with loss of expression of the wildtype allele [25, 26]. In a single study of 6 hereditary DGC cancers, inactivation of the wild-type allele could be attributed to promoter hypermethylation in 5 (83%) of cases [26]. This finding warrants verification in a larger cohort as abnormal promoter methylation in early cancers could potentially form the basis of a screening test.




Fig. 2 DGC and LBC associated *CDH1* germline mutations. Mutations shown above *CDH1* gene schematic occur in families with DGC history and those below *CDH1* occur in families with an additional or exclusive LBC history. In addition to the known *CDH1* germline mutations compiled by Kaurah et al. [4], the recent mutation in an

LBC family [9] and novel mutation from this paper are shown and identified below the symbol denoting mutation type. * Denotes the halfway point of the *CDH1* coding sequence (1324 or the start of exon 10)

Lobular breast cancer and diffuse gastric cancer: loss of E-cadherin

Currently germline mutations in single genes account for approximately 5–10% of breast cancer [27]. High penetrance genes such as *BRCA1* and 2 account for 3–8%, and *TP53* and *PTEN* as seen in Li-Fraumeni and Cowden syndrome together only account for <0.1% of breast cancer diagnoses [28]. Other medium and low penetrance genes such as *CHK2*, *BRIP1*, *PALB2* and *ATM* [29–32] have been identified, however, there still remains a proportion of hereditary breast cancer not yet determined. LBC accounts for approximately 10% of all breast cancers compared to the other major histologic subtype, invasive ductal carcinoma (IDC) [33]. Several factors suggest that LBC has a stronger hereditary basis relative to IDC, such as the higher frequency of bilateral disease [33], and also where excess familiarity of LBC has been observed in population studies [34]. LBCs compose only 3% and 9% of the breast cancer tumour types seen in germline *BRCA 1* and 2 mutation carriers, respectively [35], illustrating that the genetic risk factors for the majority of cases are unaccounted for by these genes.

The histology of LBC is characterized by infiltrative cancer cells which are isolated, highly dispersive and demonstrate a growth pattern with scattered and single files of tumor cells dispersed in stromal tissue [36]. This pathologic appearance is remarkably similar to DGCs and both LBC and DGC demonstrate characteristic mucinous, signet ring cells. This is not unexpected as E-cadherin staining is absent in 85% of sporadic invasive LBC [37] and somatic *CDH1* mutations have been identified in 56% of sporadic LBCs [38]. Furthermore, in IDC, somatic *CDH1* mutations are not found [38] and complete loss of E-cadherin expression is an uncommon feature. As loss of E-cadherin expression is a distinctive trait of both LBCs and DGCs, it likely contributes to the unique histopathologic features shared by the two cancers.

There are some differences with regard to the nature of the mutations seen in LBC and DGC. Generally mutations associated with sporadic LBC have been found to be nonsense or frameshift mutations [39] which encode truncated, non-functional proteins, whereas in sporadic DGC, mutations have generally been found to be splice site and in-frame mutations [11]. In sporadic LBC, mutations in *CDH1* are spread throughout the gene [11] compared with the mutations seen in sporadic DGC which tend to cluster. Germline *CDH1* mutations associated with DGC and/or LBC occur throughout the gene (Fig. 2). However, when the DGC and LBC associated *CDH1* mutations are tabulated and compared based on their 3' or 5' positions relative to the halfway point of the *CDH1* coding sequence (1324 or the start of exon 10), LBC

associated mutations show a statistically significant trend towards clustering at the 3' end (Fisher's exact test, two-tailed *P*-value equals 0.0467) (Fig. 2). As this association is of weak statistical significance, it is unlikely to impact clinical testing strategies. Future analyses of novel germline LBC-associated *CDH1* mutations should help to confirm this observation. Another difference between the molecular genetics of the two types of cancers, is that in sporadic LBC, silencing of E-cadherin expression is generally accomplished by a mutation in one allele in combination with loss of heterozygosity (LOH) or promoter hypermethylation in the remaining allele [40]. This is in contrast to sporadic DGC, where biallelic inactivation is achieved by mutations in one allele in concert with promoter hypermethylation in the other [41].

We have recently identified a truncating germline *CDH1* mutation in an LBC family where analysis of the tumour was suggestive of partial LOH in the WT allele [9]. Our current case demonstrates a germline *CDH1* mutation (1565 + 1G > A) in a predominantly breast cancer family, which is predicted to disrupt splicing. The mutation is in the same conserved position as a previously reported mutation (1565 + 1G > T) which was found in an Arabian HDGC family with no recorded history of breast cancer [42]. Moreover, a previous study reported a germline missense mutation in a proband with LBC but did not detail family history, or functionally characterize the missense mutation [43]. These examples demonstrate the need for further studies of germline mutations in LBC families in order to determine the mutation frequency and potential genotype-phenotype correlations.

Lobular breast cancer and HDGC

Breast cancer has been observed in HDGC kindreds to the extent where clustering of LBCs within HDGC families has led to the misclassification of families as breast cancer kindreds who test negative for *BRCA1/2* mutations [4]. In 1998, Keller described the first case of histologically defined LBC in association with HDGC [5]. Since then, several more HDGC families with associated breast cancer were reported where it was observed, that these cases were LBCs when pathology was available [4, 6–8].

Prior to establishment of the association between HDGC and LBC, several efforts to determine whether *CDH1* was a breast cancer susceptibility gene were attempted in view of the well-recognised phenotype of loss of E-cadherin expression displayed by the breast cancer subtype. For various reasons these studies failed to demonstrate the link. Rahman et al. examined 65 cases of lobular carcinoma in situ, however did not pre-screen the cases based on family history and included a wide age range, from 26 to

71 years, not necessarily in keeping with the usual age of onset seen in hereditary cancer syndromes [44]. Salashor examined 19 breast cancer tumours exhibiting LOH at the *CDH1* locus, however of those, only 3 were confirmed to be pure LBC or mixed LBC/IDC pathology [45]. Lei examined 13 familial LBC cases and found no mutations, however did not define the extent of the family history [46].

Penetrance data based on 11 HDGC families, estimated the cumulative risk for LBC for female mutation carriers to be 39% (95% CI, 12–84%) by 80 years of age [47]. More recently we have published an estimated cumulative risk for breast cancer for females by the age of 75 years as being 52% (95% CI, 29–94%) from analysis of 4 predominantly gastric cancer pedigrees from Newfoundland with the 2398delC *CDH1* founder mutation [4]. This is with the caveat that LBC risk for *CDH1* mutation carriers has been assessed within high risk HDGC families, leading to a potential ascertainment bias and underestimation of the role of *CDH1* mutations in LBC development. To accommodate for this we have begun analysis of *CDH1* mutations within familial lobular breast cancer families or those families ascertained through a relatively young index case with confirmed LBC and have found germline *CDH1* mutations in these kindreds [9].

Clinical implications of *CDH1* associated LBC risk

At this time, it seems reasonable to conclude that at least four groups of women are at increased risk for LBC: women with LBC and a family history of breast cancer, women with a known *CDH1* mutation, women from families with diffuse gastric cancer in whom no *CDH1* mutation has yet been identified; and women with a germline *BRCA2* mutation. Since there has not yet been a large population based study of the prevalence of *CDH1* mutations among women with lobular breast cancer, it is premature to recommend genetic evaluation to women with a family history of breast cancer unless, at the very least, one of the breast cancers can be shown to have been lobular. Additional research can be expected to provide better guidance for these families.

Although there are not yet definitive data available on surveillance or risk reduction programs for women with known *CDH1* mutations or untested women from *CDH1*-positive families, the high lifetime risk of LBC (39–52%) [4, 47] that these women face mandates their careful management. We suggest that they follow the recommendations for other high-risk women with hereditary breast cancer predisposition. This subgroup should be advised to practice breast self-examination; and to have annual mammograms, and semiannual clinical breast examination,

beginning at least by age 30. There is certainly interest in regular bilateral breast MRI, as lobular breast cancer are known to frequently elude mammographic detection because they do not form masses or develop calcifications. These women can also be counseled to consider hormonal chemoprevention, since most LBCs are estrogen receptor positive [33], and both tamoxifen and raloxifene reduce the risk of estrogen receptor positive [48, 49] breast cancers in randomized trials. In addition, the risk reduction was greatest with both agents in women with lobular carcinoma in situ [50].

Prophylactic mastectomy may also be considered an option by some *CDH1*-positive women, particularly those who have been previously diagnosed with breast cancer in one breast or those who have had to undergo multiple biopsies for abnormal clinical findings. Several studies have reported a 90% reduction in breast cancer incidence with prophylactic mastectomy among women with a strong family history or with a germline *BRCA1* or *BRCA2* mutation [51, 52]. The published series include some lobular breast cancers, but not at numbers sufficient to permit meaningful subset analysis at this time.

Management of hereditary diffuse gastric cancer

Penetrance studies examining data from HDGC families, have estimated the lifetime risk of developing gastric cancer by age 75 and 80 respectively, to be from 40–67% in men, to 63–83% in women [4, 47]. Although identification of germline *CDH1* mutations has enabled a significant proportion of HDGC families to utilise predictive testing to determine their individual risks of GC within *CDH1* mutation positive pedigrees, unfortunately screening for DGC is ineffective and the current recommendation is for consideration of prophylactic gastrectomy in mutation positive individuals. Positron emission tomography [53] and chromoendoscopic-directed biopsies [54] have been proposed over basic endoscopy as more sensitive means of screening carriers, however screening methods have been consistently undermined by the recurrent discovery of multifocal DGC lesions underlying normal mucosa in prophylactic gastrectomy specimens of individuals with recent negative screening [4, 55, 56]. Regardless of the current limitations of screening, it is currently recommended that consideration for genetic testing and screening begin in at risk individuals in the late teens or early twenties [4] and that prophylactic total gastrectomy be considered in the early twenties for mutation carriers. Female mutation carriers will need specialized counseling to the potential nutritional effects on pregnancy following gastrectomy [57]. Further studies are currently underway to examine the quality of life impact of

prophylactic gastrectomies. In the case report herein, although there was a GC in the maternal grandfather, the family history was more striking for the large number of breast cancer cases. This highlights the particular challenges we currently face with regard to counseling these families which appear to be mainly breast cancer, as it is unknown if the penetrance of DGC in this family is as high as it is in other HDGC pedigrees.

Conclusion

HDGC is one of a number of hereditary cancer syndromes that feature both an increased breast and gastric cancer risk (Table 1). In general, a lack of shared genetic risks for most breast and GI cancers was suggested through a recent study of 13,023 genes in 11 breast and 11 colon cancer cell lines in which the only commonly mutated gene between these two cancer types is *p53* [58]. This likely reflects underlying differences in the biology of these diseases, however also highlights the unique nature of germline mutations in the *CDH1* gene which are strongly associated with specific histologically defined subtypes of breast and GI cancer, namely LBC and DGC which are both part of the HDGC syndrome.

With the recent demonstration of a *CDH1* mutation in a family ascertained through an index case of LBC and in view of the additional new mutation in a predominantly breast cancer family that we have described here, the evidence for establishing LBC as part of the HDGC syndrome is strong. There now is a need for establishing the prevalence of *CDH1* mutations in LBC families to avoid the ascertainment bias generated from only looking at cases from families identified because of their family history of GC. It is not currently known what the risk of GC is in these families which present predominantly as having a susceptibility to breast cancer and therefore identification of *CDH1* as a true susceptibility gene for LBC could result in *CDH1* screening and effective risk reduction strategies for selected breast cancer families and further studies examining their risk for gastric and other cancers.

Most hereditary cancer syndromes are associated with cancer risk involving multiple organs. Here we have discussed germline *CDH1* mutations and the risks with regard to DGC and LBC, however as the recognised spectrum of related cancers broadens, more affected families will be identified and successfully managed with regard to avoidance of specific cancer risks. Longer life expectancy in individuals with penetrant mutations could potentially lead to the development of different, later onset disease as yet to be identified in these kindreds. This represents a particular challenge in hereditary cancer practice as the clinical community tends to be segregated into organ

Table 1 Other syndromes with familial susceptibility to breast and gastric cancers

Syndrome	Mode of inheritance	Associated gene(s)	Sites of primary cancer(s)	Evidence for association with the syndrome
BRCA2 Hereditary Breast/Ovarian Cancer	AD	<i>BRCA2</i>	Breast Ovary Larynx Prostate	BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 45% (95% confidence interval (CI) 31–56%) [59] Familial aggregations of both BC and GC have been reported [60] In a study of 173 families, relative risk for GC was 2.6 [61] Among Ashkenazi Jewish GC patients, the frequency of 617delT mutation is five times that of the general Ashkenazi Jewish population frequency [62] Among other cancers, GC occurred in first degree relatives when mutations were located in the ovarian cancer cluster region of exon 11 of <i>BRCA2</i> [63] BC is considered an integral tumor of the syndrome with an average cumulative risk in carriers by age 70 years of 72.8% (95% confidence interval [CI] = 67.9% to 77.7%) [64] There is a 4 times increased risk for GC [64] GC is considered an integral tumor of the syndrome with a relative risk of 213 (95% confidence interval 96–368) [65] BC is considered an integral tumor of the syndrome with a relative risk of 15.2 (95% CI 7.6–27) [65]
BRCA1 Hereditary Breast/Ovarian Cancer	AD	<i>BRCA1</i>	Breast Ovary Prostate	
Peutz-Jeghers Syndrome	AD	<i>STK11</i>	Gastrointestinal (GI) tract	

Table 1 continued

Syndrome	Mode of inheritance	Associated gene(s)	Sites of primary cancer(s)	Evidence for association with the syndrome
Cowden Syndrome	AD	<i>PTEN</i>	Breast Thyroid Endometrium	BC is considered an integral tumor of the syndrome with an incidence of 22–50% [66, 67] GC in situ has been reported in a patient with Cowden Syndrome [68]
Li-Fraumeni Syndrome	AD	<i>TP53</i> <i>CHK2</i>	Breast Adrenal cortex Connective tissue Kidney Nervous system Pancreas White blood cells	BC is frequently found in families with this cancer susceptibility syndrome [69] Chompret expanded the spectrum of cancers to include GC [70] Germline <i>TP53</i> mutations have been found in GC families without <i>CDH1</i> mutations [71–73] The 1100delC <i>CHK2</i> allele confers a 2.2 fold risk of BC to carriers [29], however germline mutations in GC kindreds have not been identified [74]
Familial Adenomatous Polyposis	AD	<i>APC</i>	Colon and rectum Duodenum Thyroid Pancreas	Literature review by Shimoyama et al. totalled 30 reported cases of GC and FAP [76] 47% to 49% of primary BCs had promoter hypermethylation at the <i>APC</i> locus [77, 78] 23% of LBCs have been shown to have LOH of <i>APC</i> [43]
Lynch Syndrome (Hereditary Nonpolyposis Colon Cancer (HNPCC))	AD	<i>hMSH2</i> <i>hMLH1</i> <i>hMSH6</i> <i>hPMS1</i> <i>hPMS2</i>	Colon and rectum Endometrium Stomach Small intestine Urothelium Kidney Ovary Skin Pancreas Brain White blood cells Biliary tract White blood cells	Gastric cancer accounted for 5% of cancers in families harboring <i>MLH1</i> or <i>MSH2</i> mutations [76] <i>hMLH1</i> mutations in large kindred segregated with BCs exhibiting microsatellite instability (MSI) [79] A slight increased incidence of BC was seen in <i>hMLH1</i> mutation carriers [80] Germline <i>hMSH2</i> mutation carrier with BC exhibited LOH for <i>hMSH2</i> in tumors analyzed [81] Analysis of primary invasive BCs demonstrated that 25% of tumours were immunonegative for MSH2 staining [82]
Ataxia-telangiectasia (AT)	AR	<i>ATM</i>	White blood cells	Mutations causing AT in homozygotes, confer susceptibility to BC in heterozygotes, where women with <i>ATM</i> mutations have a ~2-fold risk of BC and ~15% of these women will develop the disease [32] GC has been reported in association with the syndrome [83–85] There is evidence of excess risks of GC in heterozygotes (RR = 3.39, 95% CI = 0.86 to 13.4) [86]

Table 1 continued

Syndrome	Mode of inheritance	Associated gene(s)	Sites of primary cancer(s)	Evidence for association with the syndrome
Xeroderma pigmentosum	AR	XPA ERCC3 (XPB) XPC ERCC2(XPD) DDB2(XPE) ERCC4(XPF) ERCC5(XPG) POLH(XP-V)	Skin Eyes	BC and GC have both independently been reported with the syndrome [87,88]
Werner Syndrome	AR	WRN	Connective tissue Skin Thyroid	GC has been reported in association with the syndrome [89] There are no reports of BC in association with Werner syndrome. Although, there is evidence supporting WRN as a low-penetrance familial BC susceptibility gene, where patients harboring both WRN Cys1367Arg or TP53 MspI variants had an increased BC risk (OR = 3.39, 95% CI 1.19–9.71) [90]

AD = autosomal dominant, AR = autosomal recessive

specific specialties where as the cancer risks and the risk reduction strategies for germline mutation carriers require a variety of expertise. The medical needs of the HDGC families are therefore best served through an engaged multidisciplinary team.

Acknowledgements This work was supported in part by the National Cancer Institute of Canada (NCIC) and the British Columbia/Yukon Territory chapter of the Canadian Breast Cancer Foundation. DGH is a Michael Smith Foundation for Health Research Senior Scholar.

Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

References

1. Crew KD, Neugut AI (2006) Epidemiology of gastric cancer. *World J Gastroenterol* 3:354–362
2. Henson DE, Dittus C, Younes M et al (2004) Differential trends in the intestinal and diffuse types of gastric carcinoma in the United States, 1973–2000: increase in the signet ring cell type. *Arch Pathol Lab Med* 7:765–770
3. Guilford P, Hopkins J, Harraway J et al (1998) E-cadherin germline mutations in familial gastric cancer. *Nature* 6674: 402–405
4. Kaurah P, MacMillan A., Boyd N et al (2007) Founder and recurrent CDH1 mutations in families with hereditary diffuse gastric cancer. *JAMA* 21:2360–2372
5. Keller G, Vogelsang H, Becker I et al (1999) Diffuse type gastric and lobular breast carcinoma in a familial gastric cancer patient with an E-cadherin germline mutation. *Am J Pathol* 2: 337–342
6. Suriano G, Yew S, Ferreira P et al (2005) Characterization of a recurrent germ line mutation of the E-cadherin gene: implications for genetic testing and clinical management. *Clin Cancer Res* 15:5401–5409
7. Oliveira C, Bordin MC, Grehan N et al (2002) Screening E-cadherin in gastric cancer families reveals germline mutations only in hereditary diffuse gastric cancer kindred. *Hum Mutat* 5:510–517
8. Brooks-Wilson AR, Kaurah P, Suriano G et al (2004) Germline E-cadherin mutations in hereditary diffuse gastric cancer: assessment of 42 new families and review of genetic screening criteria. *J Med Genet* 7:508–517
9. Masciari S, Larsson N, Senz J et al (2007) Germline E-Cadherin mutations in familial lobular breast cancer. *J Med Genet* 44: 726–731
10. Graziano F, Humar B, Guilford P (2003) The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: from the laboratory to clinical practice. *Ann Oncol* 12:1705–1713
11. Berx G, Becker KF, Hofler H et al (1998) Mutations of the human E-cadherin (CDH1) gene. *Hum Mutat* 4:226–237
12. Aberle H, Schwartz H, Kemler R (1996) Cadherin-catenin complex: protein interactions and their implications for cadherin function. *J Cell Biochem* 4:514–523
13. Thoreson MA, Anastasiadis PZ, Daniel JM et al (2000) Selective uncoupling of p120(ctn) from E-cadherin disrupts strong adhesion. *J Cell Biol* 1:189–202

14. Xiao K, Oas RG, Chiasson CM et al (2007) Role of p120-catenin in cadherin trafficking. *Biochim Biophys Acta* 1:8–16
15. Vlemminckx K, Vakaet L Jr, Mareel M et al (1991) Genetic manipulation of E-cadherin expression by epithelial tumor cells reveals an invasion suppressor role. *Cell* 1:107–119
16. Wijnhoven BP, Dinjens WN, Pignatelli M (2000) E-cadherin-catenin cell–cell adhesion complex and human cancer. *Br J Surg* 8:992–1005
17. Novak A, Dedhar S (1999) Signaling through beta-catenin and Lef/Tcf. *Cell Mol Life Sci* 5–6:523–537
18. Orsulic S, Huber O, Aberle H et al (1999) E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. *J Cell Sci Pt* 8:1237–1245
19. Aoki K, Taketo MM (2007) Adenomatous polyposis coli (APC): a multi-functional tumor suppressor gene. *J Cell Sci Pt* 19:3327–3335
20. Carneiro F, Huntsman DG, Smyrk TC et al (2004) Model of the early development of diffuse gastric cancer in E-cadherin mutation carriers and its implications for patient screening. *J Pathol* 2:681–687
21. De Leeuw WJ, Bex G, Vos CB et al (1997) Simultaneous loss of E-cadherin and catenins in invasive lobular breast cancer and lobular carcinoma in situ. *J Pathol* 4:404–411
22. Becker KF, Atkinson MJ, Reich U et al (1994) E-cadherin gene mutations provide clues to diffuse type gastric carcinomas. *Cancer Res* 14:3845–3852
23. Becker KF, Hoffer H (1995) Frequent somatic allelic inactivation of the E-cadherin gene in gastric carcinomas. *J Natl Cancer Inst* 14:1082–1084
24. Machado JC, Soares P, Carneiro F et al (1999) E-cadherin gene mutations provide a genetic basis for the phenotypic divergence of mixed gastric carcinomas. *Lab Invest* 79:459–465
25. Carneiro F, Oliveira C, Suriano G et al (2007) Molecular pathology of familial gastric cancer. *J. Clin. Pathol*
26. Grady WM, Willis J, Guilford PJ et al (2000) Methylation of the CDH1 promoter as the second genetic hit in hereditary diffuse gastric cancer. *Nat Genet* 1:16–17
27. Thull DL, Vogel VG (2004) Recognition and management of hereditary breast cancer syndromes. *Oncologist* 1:13–24
28. Rosman DS, Kaklamani V, Pasche B (2007) New insights into breast cancer genetics and impact on patient management. *Curr Treat Options Oncol* 1:61–73
29. CHEK2 Breast Cancer Case-Control Consortium (2004) CHEK2*1100delC and susceptibility to breast cancer: a collaborative analysis involving 10,860 breast cancer cases and 9,065 controls from 10 studies. *Am J Hum Genet* 6:1175–1182
30. Seal S, Thompson D, Renwick A et al (2006) Truncating mutations in the Fanconi anemia J gene BRIP1 are low-penetrance breast cancer susceptibility alleles. *Nat Genet* 11:1239–1241
31. Rahman N, Seal S, Thompson D et al (2007) PALB2, which encodes a BRCA2-interacting protein, is a breast cancer susceptibility gene. *Nat Genet* 2:165–167
32. Ahmed M, Rahman N (2006) ATM and breast cancer susceptibility. *Oncogene* 43:5906–5911
33. Arpino G, Bardou VJ, Clark GM et al (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. *Breast Cancer Res* 3:R149–156
34. Allen-Brady K, Camp NJ, Ward JH et al (2005) Lobular breast cancer: excess familiarity observed in the Utah Population Database. *Int J Cancer* 4:655–661
35. Lakhani SR, Gusterson BA, Jacquemier J et al (2000) The pathology of familial breast cancer: histological features of cancers in families not attributable to mutations in BRCA1 or BRCA2. *Clin Cancer Res* 3:782–789
36. Moll R, Mitze M, Frixen UH et al (1993) Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas. *Am J Pathol* 6:1731–1742
37. Bex G, Van Roy F (2001) The E-cadherin/catenin complex: an important gatekeeper in breast cancer tumorigenesis and malignant progression. *Breast Cancer Res* 5:289–293
38. Bex G, Cleton-Jansen AM, Strumane K et al (1996) E-cadherin is inactivated in a majority of invasive human lobular breast cancers by truncation mutations throughout its extracellular domain. *Oncogene* 9:1919–1925
39. Bex G, Cleton-Jansen AM, Nollet F et al (1995) E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. *EMBO J* 24:6107–6115
40. Droufakou S, Deshmane V, Roylance R et al (2001) Multiple ways of silencing E-cadherin gene expression in lobular carcinoma of the breast. *Int J Cancer* 3:404–408
41. Machado JC, Oliveira C, Carvalho R et al (2001) E-cadherin gene (CDH1) promoter methylation as the second hit in sporadic diffuse gastric carcinoma. *Oncogene* 12:1525–1528
42. Humar B, Toro T, Graziano F et al (2002) Novel germline CDH1 mutations in hereditary diffuse gastric cancer families. *Hum Mutat* 5:518–525
43. Sarrio D, Moreno-Bueno G, Hardisson D et al (2003) Epigenetic and genetic alterations of APC and CDH1 genes in lobular breast cancer: relationships with abnormal E-cadherin and catenin expression and microsatellite instability. *Int J Cancer* 2:208–215
44. Rahman N, Stone JG, Coleman G et al (2000) Lobular carcinoma in situ of the breast is not caused by constitutional mutations in the E-cadherin gene. *Br J Cancer* 3:568–570
45. Salahshor S, Haixin L, Huo H et al (2001) Low frequency of E-cadherin alterations in familial breast cancer. *Breast Cancer Res* 3:199–207
46. Lei H, Sjoberg-Margolin S, Salahshor S et al (2002) CDH1 mutations are present in both ductal and lobular breast cancer, but promoter allelic variants show no detectable breast cancer risk. *Int J Cancer* 2:199–204
47. Pharoah PD, Guilford P, Caldas C et al (2001) Incidence of gastric cancer and breast cancer in CDH1 (E-cadherin) mutation carriers from hereditary diffuse gastric cancer families. *Gastroenterology* 6:1348–1353
48. Fisher B, Costantino J, Redmond C et al (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. *N Engl J Med* 8:479–484
49. Land SR, Wickerham DL, Costantino JP et al (2006) Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. *JAMA* 23:2742–2751
50. Wolmark N, Dunn BK (2001) The role of tamoxifen in breast cancer prevention: issues sparked by the NSABP Breast Cancer Prevention Trial (P-1). *Ann NY Acad Sci* 99–108
51. Rebbeck TR, Friebel T, Lynch HT et al (2004) Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. *J Clin Oncol* 6:1055–1062
52. Robson M, Svahn T, McCormick B et al (2005) Appropriateness of breast-conserving treatment of breast carcinoma in women with germline mutations in BRCA1 or BRCA2: a clinic-based series. *Cancer* 1:44–51
53. van Kouwen MC, Drenth JP, Oye WJ et al (2004) [¹⁸F]Fluoro-2-deoxy-D-glucose positron emission tomography detects gastric carcinoma in an early stage in an asymptomatic E-cadherin mutation carrier. *Clin Cancer Res* 19:6456–6459

54. Shaw D, Blair V, Framp A et al (2005) Chromoendoscopic surveillance in hereditary diffuse gastric cancer: an alternative to prophylactic gastrectomy? *Gut* 4:461–468
55. Huntsman DG, Carneiro F, Lewis FR et al (2001) Early gastric cancer in young, asymptomatic carriers of germ-line E-cadherin mutations. *N Engl J Med* 25:1904–1909
56. Norton JA, Ham CM, Van Dam J et al (2007) CDH1 truncating mutations in the E-cadherin gene: an indication for total gastrectomy to treat hereditary diffuse gastric cancer. *Ann Surg* 6:873–879
57. Lynch HT, Grady W, Suriano G et al (2005) Gastric cancer: new genetic developments. *J Surg Oncol* 3:114–133; discussion 133
58. Sjoblom T, Jones S, Wood LD et al (2006) The consensus coding sequences of human breast and colorectal cancers. *Science* 579:268–274
59. Antoniou A, Pharoah PD, Narod S et al (2003) Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case Series unselected for family history: a combined analysis of 22 studies. *Am J Hum Genet* 5:1117–1130
60. Jakubowska A, Nej K, Huzarski T et al (2002) BRCA2 gene mutations in families with aggregations of breast and stomach cancers. *Br J Cancer* 8:888–891
61. Cancer risks in BRCA2 mutation carriers. The Breast Cancer Linkage Consortium (1999) *J Natl Cancer Inst* 15:1310–1316
62. Figer A, Irmin L, Geva R et al (2001) The rate of the 6174delT founder Jewish mutation in BRCA2 in patients with non-colonic gastrointestinal tract tumours in Israel. *Br J Cancer* 4:478–481
63. Risch HA, McLaughlin JR, Cole DE et al (2001) Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer. *Am J Hum Genet* 3:700–710
64. Brose MS, Rebbeck TR, Calzone KA et al (2002) Cancer risk estimates for BRCA1 mutation carriers identified in a risk evaluation program. *J Natl Cancer Inst* 18:1365–1372
65. Giardiello FM, Brensinger JD, Tersmette AC, Goodman SN, Petersen GM, Booker SV, Cruz-Correa M, Offerhaus JA (2000) Very high risk of cancer in familial Peutz-Jeghers syndrome. *Gastroenterology* 6:1447–1453
66. Starink TM, van der Veen JP, Arwert F et al (1986) The Cowden syndrome: a clinical and genetic study in 21 patients. *Clin Genet* 3:222–233
67. Brownstein M.H., Wolf M., Bikowski J.B. (1978) Cowden's disease: a cutaneous marker of breast cancer. *Cancer* 6:2393–2398
68. Hamby LS, Lee EY, Schwartz RW (1995) Parathyroid adenoma and gastric carcinoma as manifestations of Cowden's disease. *Surgery* 1:115–117
69. Birch JM, Alston RD, McNally RJ et al (2001) Relative frequency and morphology of cancers in carriers of germline TP53 mutations. *Oncogene* 34:4621–4628
70. Chompret A, Abel A, Stoppa-Lyonnet D et al (2001) Sensitivity and predictive value of criteria for p53 germline mutation screening. *J Med Genet* 1:43–47
71. Keller G, Vogelsang H, Becker I et al (2004) Germline mutations of the E-cadherin(CDH1) and TP53 genes, rather than of RUNX3 and HPP1: contribute to genetic predisposition in German gastric cancer patients. *J Med Genet* 6:e89
72. Kim IJ, Kang HC, Shin Y et al (2004) A TP53-truncating germline mutation (E287X) in a family with characteristics of both hereditary diffuse gastric cancer and Li-Fraumeni syndrome. *J Hum Genet* 49:591–595
73. Oliveira C, Ferreira P, Nabais S et al (2004) E-Cadherin (CDH1) and p53 rather than SMAD4 and Caspase-10 germline mutations contribute to genetic predisposition in Portuguese gastric cancer patients. *Eur J Cancer* 12:1897–1903
74. Kimura K, Shimura K, Yoshimura K et al (2000) Absence of germline CHK2 mutations in familial gastric cancer. *Jpn J Cancer Res* 9:875–879
75. Shimoyama S, Aoki F, Kawahara M et al (2004) Early gastric cancer development in a familial adenomatous polyposis patient. *Dig Dis Sci* 2:260–265
76. Dulaimi E, Hillinck J, Ibanez de Caceres I et al (2004) Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients. *Clin Cancer Res* 18(Pt 1):6189–6193
77. Shinozaki M, Hoon DS, Giuliano AE et al (2005) Distinct hypermethylation profile of primary breast cancer is associated with sentinel lymph node metastasis. *Clin Cancer Res* 6:2156–2162
78. Geary J, Sasieni P, Houlston R et al (2007) Gene-related cancer spectrum in families with hereditary non-polyposis colorectal cancer (HNPCC). *Fam Cancer*
79. Risinger JI, Barrett JC, Watson P et al (1996) Molecular genetic evidence of the occurrence of breast cancer as an integral tumor in patients with the hereditary nonpolyposis colorectal carcinoma syndrome. *Cancer* 9:1836–1843
80. Scott RJ, McPhillips M, Meldrum CJ et al (2001) Hereditary nonpolyposis colorectal cancer in 95 families: differences and similarities between mutation-positive and mutation-negative kindreds. *Am J Hum Genet* 1:118–127
81. Westenend PJ, Schutte R, Hoogmans MM et al (2005) Breast cancer in an MSH2 gene mutation carrier. *Hum Pathol* 12:1322–1326
82. Spagnoletti I, Pizzi C, Galiotta A et al (2004) Loss of hMSH2 expression in primary breast cancer with p53 alterations. *Oncol Rep* 4:845–851
83. Haerer AF, Jackson JF, Evers CG (1969) Ataxia-telangiectasia with gastric adenocarcinoma. *JAMA* 10:1884–1887
84. Watanabe A, Hanazono H, Sogawa H et al (1977) Stomach cancer of a 14-year-old boy with ataxia-telangiectasia. *Tohoku J Exp Med* 2:127–131
85. Bigbee WL, Langlois RG, Swift M et al (1989) Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia. *Am J Hum Genet* 3:402–408
86. Thompson D, Duedal S, Kirner J et al (2005) Cancer risks and mortality in heterozygous ATM mutation carriers. *J Natl Cancer Inst* 11:813–822
87. Milo Y, Deutsch AA, Zahavi S et al (1994) Xeroderma pigmentosum with recurrent infiltrating ductal carcinoma of breast. *Postgrad Med J* 821:240–241
88. Puig L, Marti R, Matias-Guiu X et al (1985) Gastric adenocarcinoma in a patient with xeroderma pigmentosum. *Br J Dermatol* 5:632–633
89. Tsuchiya H, Tomita K, Ohno M et al (1991) Werner's syndrome combined with quintuplicate malignant tumors: a case report and review of literature data. *Jpn J Clin Oncol* 2:135–142
90. Wirttenberger M, Frank B, Hemminki K et al (2006) Interaction of Werner and Bloom syndrome genes with p53 in familial breast cancer. *Carcinogenesis* 8:1655–1660